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Chronic kidney disease (CKD) lead to secondary hyperparathyroidism 
(sHPT) that caused by phosphate retention and hypocalcemia. This condition 
known as mineral and bone disorder (CKD-MBD). The increase in parathyroid 
hormone would increase bone turnover that result in an increased risk of 
bone fractures, and vascular calcification. These will increase the levels of 
tartrate-resistant acid phosphatase 5b (TRAP5b), and bone-specific alkaline 
phosphatase (b-ALP), which is a marker of bone turnover, and also dickkopf-
related protein 1 (DKK-1), which is an inhibitor of the Wnt pathway. 
Secondary hyperparathyroidism in CKD also caused by calcitriol deficiency. 
Paricalcitol is a synthetic calcitrol analogue used to reduce parathyroid 
hormone (iPTH) with minimal calcemic and phosphatemic activity. Vitamin 
D receptor activation by paricalcitol will decrease TRAP5b, b-ALP, and DKK-
1. In this study we reported 9 cases of CKD-MBD with Hemodialysis (HD) and 
associated with sHPT. Four of nine cases received 5μg paricalcitol every HD 
(twice a week) while the others five is not. Level of iPTH, phosphate, calcium, 
TRAP5b, b-ALP, and DKK-1 were measured before initiation of study and 
after three months treatment. According to this study, the paricalcol 
administration suppresses the increase in iPTH level, bone turnover and 
vascular calcification showed by decreasing or supresses the increase b-ALP,  
TRAP5b, DKK-1  leves without increasing calcium and phosphate levels. 
Keywords: secondary hyperparathyroidism, paricalcitol, TRAP5b, b-ALP, 
DKK-1. 
 
 
INTRODUCTION 
Deranged mineral metabolism in patient 
with chronic kidney disease (CKD) result not only 
in bone disease, but a higher risk of cardiovascular 
disase and reduce survival, through the 
developement of vascular calcification, which is 
known as CKD-Mineral and Bone Disorder (CKD-
MBD). CKD-MBD is a systemic condition that 
manifests as abnormalities in parathyroid hormone 
(PTH), calcium, phosphorus and vitamin D; bone 
abnormalities and extraskeletal calcification which 
shown by Tartrate-resistant acid phosphatase 5b 
(TRAP-5b), and bone-specific alkaline phosphatase 
(b-ALP) (Fukugawa, et al., 2013). In patients with 
CKD-MBD a calcitriol deficiency leads to the 
development of secondary HPT (sHPT) both by 
direct and indirect effects (Llach, et al., 1998). 
Beside that, calcitriol deficiency also reduces 
activity of vitamin D receptor that suppressing 
dickkopf-related protein 1 (DKK-1) expression 
(Cianferotti, and Demay, 2007). 
 
Paricalcitol is an analogue of calcitriol that 
suppresses iPTH secretion while having only minor 
effects on serum level of calcium and phosphate 
(Lacy, et al., 2011). Levels of  iPTH have a positive 
correlation with bone turnover  rate (ie, both 
resorption and formation) and vascular 
calcification (Jilka et al., 2010 and Shetty et al., 
2016). So that Paricalcitol therapy  in CKD-MBD 
effectively decreases osteoblast activity (b-ALP 
level) (Coyne et al., 2013), serum TRAP-5b as a 
marker of bone resorption and DKK-1 as an 
inhibitor   of   Wnt  pathway   that    have     a                              role 
in    vascular     calcification. The aim of the study 
was to analyze changes of serum levels calcium, 
phosphate,   intact    parathyroid    hormone   (iPTH), 
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TRAP5b, b-ALP, and DKK-1 on CKD-MBD patient 
with sHPT who received and without paricalcitol 
for three months. 
 
MATERIAL AND METHODS 
This study was cohort prospective 
observational to evaluate  the effect of  paricalcitol 
in CKD-MBD associated with secondary 
hyperparathyroidism. The inclusion criteria              
were hemodialysis patient with end stage                 
renal disease and MBD, age more than 18 years, 
iPTH serum concentration ≥150pg/mL, calcium 
serum concentration ≤11mg/Dl, phosphate               
serum concentration ≤10.2mg/dL, with or without 
paricalcitol therapy. The exclusion criteria was 
patient with severe liver injury with Child-                 
Pugh Score 10-15. Blood serum withdrawn  twice,  
first before paricalcitol therapy and the second was 
3 month after paricalcitol therapy.             Analyzed  
was done for the serum concentration of calcium, 
phosphate, PTH, b-ALP, TRAP5b, and DKK-1.  
 
Case ilustration  
In this study we present nine patients who 
developed CKD-MBD with hemodialysis (HD) at a 
hospital in Surabaya City, Indonesia. The patients 
grouped into 2 groups, first group contain 4 
patients with paricalcitol therapy and second     
group contain 5 patients without paricalcitol 
therapy. Baseline characteristics of nine patients 
(Table I). Serum level of calcium, phosphate, iPTH, 
TRAP-5b, b-ALP and DKK-1 were measured twice, 
before initiation of study (t0) and after 3 months 
(t1). Result of paricalcitol group (Table II) and 
without paricalcitol group (Table III). 
Besides, the correlation test was also 
performed among serum level of iPTH with 
TRAP5b, b-ALP, DKK-1 and the correlation of 
TRAP5b and b-ALP, TRAP5b and DKK-1, also b-ALP 
and DKK-1. 
Case 1: A 45-year-old man with 
hypertension, end stage renal disease (ESRD). Level 
of calcium, phosphate, iPTH, b-ALP, TRAP5B, and 
DKK-1 decreased after 3 months of paricalcitol. 
Another therapy was also given to this patient such 
as risedronate, and  lanthanum carbonate; Case 2: 
A 70-year-old man with diabetic nephropathy, 
hypertension, ESRD. Level of calcium, iPTH, b-ALP, 
and DKK-1 decreased but level of phosphate, and 
TRAP5b increased after  3 months of paricalcitol. 
Another therapy was also given to this patient such 
as lanthanum carbonate; Case 3: A 62-year-old man 
with hypertension, ESRD. Level of b-ALP, and 
TRAP5B decreased but level of calcium, phosphate, 
iPTH, and DKK-1 increased after 3 months of 
paricalcitol. During treatment level of uric acid also 
increased from 5.54mg/dL to 7.31mg/dL. Another 
therapy was also given to this patient such as 
calcium acetate; Case 4: A 64-year-old woman with 
hypertension, ESRD. Level of calcium, b-ALP, and 
DKK-1 decreased but level of phosphate, iPTH,  and 
TRAP5b increased after 3 months of paricalcitol. 
During treatment level of uric acid also increased 
from 4.83mg/dL to 6.78mg/dL. Another therapy 
was also given to this patient such as risedronate, 
and calcium acetate; Case 5: A 50-year-old man 
with diabetic nephropathy, hypertension, end 
ESRD. Patient has history of GERD with treatment 
of cisapride. Level of calcium, and DKK-1 decreased 
but level of  iPTH, b-ALP, and TRAP5b increased 
without change    on   phosphate    level    after    3    
months. Level of uric acid also increased from 
6.75mg/dL to 8.54mg/dL; Case 6: A 51-year-old 
man with hypertension, ESRD. Level of calcium,  
iPTH, b-ALP, TRAP5b, and DKK-1 increased but level 
of phosphate  decreased after 3 months. Another 
Table I. Baseline characteristics of the nine cases  
 
Patient Sex Age (yr) Etiology of ESRD 
Body surface 
area (m2) 
HD Duration  
(Months) 
Paricalcitol 1 Male 43 NDN 1.84 130 
2 Male 70 DN 1.81 68 
3 Male 62 NDN 1.92 18 
4 Female 64 NDN 1.45 33 
Without 
Paricalcitol 
5 Male 50 DN 1.89 42 
6 Male 51 NDN 2.07 54 
7 Female 75 NDN 1.52 19 
8 Male 55 DN 2.14 19 
9 Female 38 DN 1.72 37 
 
DN: Diabetic nephropathy; NDN: Non-diabetic nephropathy 
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therapy was also given to this patient such as 
calcium acetate; Case 7: A 75-year-old woman with 
hypertension, ESRD. Level of calcium, phosphate, 
and b-ALP decreased but level of iPTH, TRAP5b, and 
DKK-1 increased after 3 months. Another therapy 
was also given to this patient such as risedronate, 
and calcium acetate; Case 8: A 55-year-old man 
with diabetic nephropathy, hypertension, ESRD. 
Level of phosphate, iPTH, b-ALP, TRAP5B, and DKK-
1 increased but level of calcium decreased after 3 
months; Case 9: A 38-year-old woman with diabetic 
nephropathy, hypertension, ESRD. Level of iPTH, b-
ALP, TRAP5B, and DKK-1 increased but level of 
calcium and phosphate decreased after 3 months. 
Another therapy was also given to this patient such 
as calcium acetate. 
 
RESULT AND DISCUSSION 
Chronic Kidney Disease-Mineral Bone 
Disorder (CKD-MBD) is a systemic disorder of 
mineral and bone metabolism due to CKD 
manifested by abnormalities of calcium, 
phosphorus, PTH, or vitamin D metabolism, 
abnormalities in bone turnover, mineralization, 
volume, linear growth, or strength, vascular or 
other soft tissue calcification (KDIGO, 2009). As 
kidney function continues to decline and the GFR 
falls less than 30 mL/min/1.73m2 (0.29 mL/s/m2), 
phosphorus excretion continues to decrease and 
calcitriol production decreases, causing PTH levels 
to begin to rise significantly, leading to sHPT 
(Dipiro, 2013). 
 
The excessive production of PTH leads to 
hyperplasia of the parathyroid glands, which 
decreases the sensitivity of the parathyroid glands 
to serum calcium levels and calcitriol feedback, 
further promoting sHPT. The most dramatic 
consequence of sHPT is alterations in bone 
turnover and the development of renal 
osteodystrophy (ROD) (Dipiro, 2013). Paricalcitol 
is a synthetic vitamin D analog which binds to and 
activates the vitamin D receptors (VDR) in kidney, 
parathyroid gland, intestine and bone, thus 
reducing PTH levels and improving calcium and 
phosphate homeostasis (Lacy, et al., 2011).  
Level of iPTH in circulation reflects bone 
turnover, a better correlation of iPTH with bone 
turnover markers especially TRAP5b and b-ALP has 
been reported (Fukugawa, et al., 2013). DKK-1 
change in CKD is not only influenced by iPTH but 
also by inflammation cytokines such as IL-6               
and TNF- α (Lee and Kalluri, 2010; Yao et al.,                
2011; Yeremenko et al, 2015). Administration of 
paricalcitol could reduce iPTH level which affected 
decline bone turnover marker and inhibit                          
Wnt pathway (He et al., 2011; Cozzolino et al., 
2014). 
Table II, III, IV and V showed that before 
initiation of study (t0) serum levels of calcium  and 
phosphate were in normal range, while serum 
levels of iPTH, TRAP5b, b-ALP, and  DKK-1 
increased from normal range. This is in    
accordance with the pathophysiology of   CKD-MBD. 
There were a homeostatic between calcium and 
phosphate by increasing PTH that will increase the 
impact on bone turnover, and also decreasement of 
VDR activity. Those caused increasement of 
TRAP5b, b-ALP and DKK-1 (Fukugawa et al., 2013; 
Cianferotti and Demay, 2007; Saliba and El-Haddad, 
2009). 
 
Generally, after three month from initiation 
of study there were no changes on serum levels of 
calcium and phosphate in 2 groups, while in 
paricalcitol group iPTH and TRAP5b increased 
although not as much as in without paricalcitol 
group. b-ALP and DKK-1 increased in without 
paricalcitol group while decreased in paricalcitol 
group.  
 
The selectivity of paricalcitol in VDR has a 
little effect on absorption of calcium and phosphate 
in intestine (Lacy et al., 2011; Slatopolsky et al., 
2003). Other factors which affected levels of 
Table II Serum levels and changes of calcium, phosphate, iPTH, in paricalcitol group 
 
Patient 
Calcium (mg/dL) Phosphate (mg/dL) iPTH (pg/mL) 
t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 
1 9.5 9.2 -0.3 5.84 5.74 -0.10 627.3 578.7 -48.6 
2 10.8 10.3 -0.5 6.21 6.64 0.43 544.4 378.4 -166.0 
3 8.0 8.1 0.1 4.94 5.69 0.75 751.8 816.8 65.0 
4 9.4 8.3 -1.1 2.55 4.15 1.60 542.4 1165.0 622.6 
Mean 9.4 9.0 -0.4 4.88 5.56 0.67 616.5 734.7 118.2 
SD 1.1 1.0 0.5 1.65 1.03 0.71 98.5 338.2 349.2 
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calcium and phosphate are diet intake and other 
therapies associated with CKD-MBD such as 
phosphate binder and bisphosphonate (KDIGO, 
2009; NKF, 2013). 
 
Phosphate binder used in this study is 
calcium and lanthanum based. The mechanism of 
phosphate binder is binding phosphate from food 
intake in intestine. The risk of hypercalcemia in 
calcium-based phosphate binder is higher than do 
lanthanum-based (Salusky, 2006). Meanwhile 
administration of biphosphonate such as 
risedronate will reduce bone resorption so that no 
caused by increasing level of calcium and 
phosphate (Martin, et al., 1998; Toussaint, et al., 
2009). In paricalcitol therapy there were 2 cases 
with increase level of iPTH level. This is due the 
paricalcitol doses have not optimal yet. In this study 
the evaluation of calcium, phosphate, iPTH, 
TRAP5b, b-ALP, and DKK-1 was done before 
initiation and after three months without dose 
titration of paricalcitol, so the 30% targeted-
decrease iPTH was not achieved. According to the 
recommendation for doses titration of paricalcitol, 
dose is increased by 0.04μg/kg (maximum 16.8μg) 
to be adapted levels of iPTH and calcium 
periodically. If iPTH levels decrease <30% and 
calcium <11.5mg/dL, the paricalcitol dose should 
be increased (Lacy, et al., 2011; Martin, et al., 1998).  
Table III Serum levels and changes of b-ALP, TRAP5B, and DKK-1 in paricalcitol group 
 
Patient 
b-ALP (U/L) TRAP5B (U/L) DKK-1 (pg/mL) 
t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 
1 35.3 29.1 -6.2 7.3 8.2 0.9 2871 2275 -596 
2 22.6 21.0 -1.6 4.9 5.0 0.1 679 666 -13 
3 31.7 23.3 -8.4 6.8 6.6 -0.2 1444 2096 652 
4 92.1 89.7 -2.4 4.9 8.1 3.2 2239 1302 -937 
Mean 45.4 40.8 -4.6 6.0 7.0 1.0 1808 1585 -224 
SD 31.6 32.8 3.2 1.2 1.5 1.5 953 744 697 
 
iPTH: Intact parathyroid hormone;TRAP5b: Tartrate-resistant-acid-phosphatase 5b; b-ALP: Bone specific alkaline phosphatase; DKK-
1: Dickkopf-related protein 1; to: time before initiation of study; t1: 3 months after initiation of study; ∆ t1- t0: Change from t0 to t1 
 
Table IV Serum levels and changes of calcium, phosphate, iPTH  in without-paricalcitol group 
 
Patient 
Calcium (mg/dL) Phosphate (mg/dL) iPTH (pg/mL) 
t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 
5 9.4 9.2 -0.2 6.70 6.70 0 1212.0 1284.0 72.0 
6 8.5 9.1 0.6 9.00 8.20 -0.80 1066.0 1254.0 188.0 
7 9.0 8.7 -0.3 4.26 3.94 -0.32 694.5 929.0 234.5 
8 8.1 8.0 -0.1 2.89 3.53 0.64 199.6 474.5 274.9 
9 8.7 8.4 -0.3 8.25 6.56 -1.69 186.7 393.3 206.6 
Mean 8.7 8.7 -0.1 6.22 5.79 -0.43 671.8 867.0 195.2 
SD 0.5 0.5 0.4 2.60 1.98 0.88 475.9 420.1 76.2 
 
Table V Serum levels and changes of b-ALP, TRAP5B, and DKK-1 in without-paricalcitol group 
 
Patient 
b-ALP (U/L) TRAP5B (U/L) DKK-1 (pg/mL) 
t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 t0 t1 ∆ t1- t0 
5 88.5 128.9 40.4 10.1 15.8 5.7 2061 1640 -421 
6 52.4 79.3 26.9 4.8 7.0 2.2 3851 5928 2077 
7 61.5 54.0 -7.5 3.1 6.7 3.6 1129 1776 647 
8 48.9 72.9 24.0 4.8 5.9 1.1 1622 1747 125 
9 19.2 29.7 10.5 1.6 3.6 2.0 1492 2037 545 
Mean 54.1 73.0 18.9 4.9 7.9 2.9 2031 2626 595 
SD 24.9 36.7 18.2 3.2 4.7 1.8 1071 1852 929 
 
iPTH: Intact parathyroid hormone;TRAP5b: Tartrate-resistant-acid-phosphatase 5b; b-ALP: Bone specific alkaline phosphatase; DKK-
1: Dickkopf-related protein 1; to: time before initiation of study; t1: 3 months after initiation of study; ∆ t1- t0: Change from t0 to t1 
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The elevation of iPTH levels stimulates 
osteoclast reflected by the elevation of TRAP5b 
(Saliba and El-Haddad, 2009). This results were 
shown in case 1 and 2 -paricalcitol group, level of 
TRAP5b was still high. In case 4 the elevation of 
TRAP5b was influenced by the elevation of iPTH 
and also patient has a history hyperuricemia. In this 
condition level of TRAP5b increased (Zhao, et al., 
2012). 
Reduction level of iPTH serum is followed by 
decreasement of bone turnover (Martin, and 
Gonzales, 2007). Actually, in paricalcitol group two 
cases declined of b-ALP level although the iPTH 
level increased. This is due to the suppression 
effects of paricalcitol in osteoblast by Wnt/β-
catenin pathway, induced the inhibition in 
osteoblast proliferation and differentiation (He, et 
al., 2011; Peterlik, and Cross, 2013). Meanwhile 
decreasement of b-ALP in one case (without 
paricalcitol group) is caused by risedronate therapy 
during the study. The similarity of chemical 
structure between risedronate and pyrophosphate 
is underlining the inhibition mechanism of bone 
matrix mineralization (propagation of 
hydroxyapatite crystal), and finally could suppres 
b-ALP levels (Nancollas, et al., 2006; Bilezikian, et 
al., 2008; Recker, et al., 2008).  
Decreasement of activity stromal VDR due to 
calcitriol deficiency caused the elevation of DKK-1. 
Administration of paricalcitol was aimed to reduce 
DKK-1 by activation of VDR (Cianferotti, and 
Demay, 2007).  
In case 3, after paricalcitol therapy the level 
of DKK1 increased, it may be caused by the 
elevation of uric acid (Zhao, et al., 2012). However, 
the elevation of uric acid is not always increase 
DKK-1 level, as in case 4. This is because of other 
factors such as risedronate which had effect in 
reducing DKK-1 (Memon, et al., 2013). Furthermore, 
in case 5 (without paricalcitol group) patient has 
history of gastro-esophageal reflux disease (GERD) 
with administration of cisapride that may reduce 
DKK-1 (Storr, et al., 2000; Lyrus, et al., 2014). 
Figure 1-3 showed there were positive 
correlation between iPTH and b-ALP, TRAP5b, 
DKK-1. Figure 4 showed there was positive 
correlation beetwen TRAP5b and b-ALP Secondary 
hyperparathyroidism on CKD-MBD caused high 
turnover metabolic bone disease (Martin and 
Gonzales, 2007; Malluche, et al, 2012) and vascular 
calcification (Marinou, et al., 2012; Drueke and 
Massy, 2016) Characterization of high turnover 
metabolic    bone   disease   begins  with    increased  
osteoclast activity and followed by increased 
activity of osteoblast (Dimkovic, 2001). Figure 5 
and 6 showed no correlation between DKK-1 and 
TRAP5b; DKK-1 and b-ALP. This results maybe 
caused by level of DKK-1 is not only influenced by 
iPTH level but also by inflammation cytokines such 
as IL-6 and TNF-α (Cianferotti, and Demay, 2007; 
Yao, et al., 2011; Yeremenko, et al., 2015). 
 
 
 
 
Figure 1. Correlation between serum level iPTH and 
TRAP5b 
 
  
 
Figure 2. Correlation between serum level iPTH and 
b-ALP 
 
 
 
Figure 3. Correlation between serum level iPTH and 
DKK-1 
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Figure 4. Correlation between serum level TRAP5b 
and b-ALP 
 
 
 
Figure 5. Correlation between serum level TRAP5b 
and DKK-1 
 
 
 
Figure 6. Correlation between serum level b-ALP 
and DKK-1 
 
Of the overall results suggesting the use of 
paricalcitol suppresses iPTH increase without 
effecting an increase in serum calcium and 
phosphate. Paricalcitol administration  decrease in 
marker bone turnover suppression b-ALP and 
TRAP5b, where in paricalcitol group there was a 
smaller increase TRAP5b compared to the group 
without paricalcitol. Paricalcitol decreased DKK- 1, 
a marker of vascular calcification. 
The limitations of our study were variation 
of the patient’s comorbid i.e diabetes mellitus type 
2 and hypertension that can affect the result, 
variation of therapy regiment for CKD-MBD i.e 
phosphate binder and calcium supplement, 
variation of patient daily activity and food. To 
ensure these results are needed more samples. 
 
CONCLUSION 
The paricalcol administration suppresses the 
increase in iPTH level, bone turnover and vascular 
calcification showed by decreasing or supresses the 
increase b-ALP, TRAP5b, DKK-1  levels without 
increasing calcium and phosphate levels. 
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